Mandrake

Other Names

abu'l-ruhabu-rohadam kokuadam-köküAdamova GolowaAlrauinwortelAlraunAlrauneAlraunmännchenAlraunwurzelAlruneAlrünekenAnthropomorphosAntimelonAntimenionApemumArmesünderblumeAtropa mandragoraAtzmannautumn mandrakebaarasbayd al-jinnBombochylosbrain thiefciceronCirce's plantCirceumCircoeadevil's appledevil's herbDiamononDirkaiaDollwurzDrachenpuppedûdâ'îmdudaimDukkeurtelephant's-earErdmännchenErdmännleinEuropean mandrakeGalgenmännleingallows mannikinGeldmännleingolden apples of AphroditeGonogeonashand of gloryHausväterchenHemionusHenkerswurzelherb of CirceHundsapfeljebrûahKamarosladykinslove appleluffahluffah manganinmain de gloireMala CaninaMala TerrestriamandragormandragoraMandragora acaulisMandragora autumnalisMandragora caulescensMandragora foeminaMandragora masMandragora officinalisMandragora officinarumMandragora turcomanicaMandragora vernalismannikinMardom GhiahMatragunMatrygunaMediterranean mandrakeMehr-egiahMela Caninanam-tar-girNamtar IraNatragulyaplant of Circeraccoon berrySatan's applesorcerer's rootspring mandraketuffah al-maujanimwild lemonwitch's mannikinwomandrake

Synopsis

Mandrake (Mandragora officinarum L. / Mandragora autumnalis Bertol.)

1. Identity and Botanical Classification

Taxonomy and Nomenclature

Known botanically as Mandragora officinarum, mandrake belongs to the nightshade family (Solanaceae). The genus Mandragora comprises several closely related species; the two most pharmacologically and historically significant are Mandragora officinarum L. (spring mandrake) and Mandragora autumnalis Bertol. (autumn mandrake). When Mandragora autumnalis is regarded as the main Mediterranean species, M. officinarum is native only to north Italy and part of the coast of former Yugoslavia; M. officinarum is absent from the Levant, where it is replaced by M. autumnalis. Jackson and Berry were unable to find any differences in alkaloid composition between Mandragora officinarum (using the narrowest circumscription of this species) and Mandragora autumnalis (viewed as the main Mediterranean species).

Mandragora officinarum L. (mandrake) is one of the most ancient herbs known to mankind and yet remains one of the most misunderstood plants on earth. Common names across cultures include mandrake, European mandrake, Satan's Apple (Tufah Almajan), Alraunwurzel (German), and love apple. In many cultures, mandrake is related to magic and witchcraft, which is said to have a psychosomatic effect (especially when mandrake contains narcotic compounds) in addition to the pharmacological influence; due to its unique properties and related myths, it is not surprising that this plant has many names in many languages.

Botanical Description

The mandrake is a perennial herb with a large root, purple flowers, and poisonous yellow fruit. It is a perennial herbaceous plant in the Solanaceae family with purple or violet blooms and orange or yellow mature fruits (berries), widely distributed throughout the Mediterranean Basin. The plant grows as a basal rosette with no true aerial stem, and its thick taproot — often deeply bifurcated and anthropomorphically shaped — is the part most concentrated in alkaloids and most historically valued.

Common Forms and Preparations

Traditionally and in historical medicine, mandrake was prepared in a range of forms based on the plant part used:

Root decoction in wine (mandragora wine): Before modern surgical anesthesia, mandrake was widely used for its sedative and analgesic properties; ancient physicians like Dioscorides described preparing a wine from the root administered to patients to induce deep sleep and provide pain relief before procedures like surgery or cauterization.
Soporific sponge (spongia somnifera): A concoction for anesthesia, first mentioned in the 9th or 10th centuries AD, was made with mandrake, opium, hemlock, and henbane; the plant extracts were dissolved in water and soaked in a sponge, which was then left to dry in the sun, and when needed was placed in warm water and then placed under the patient's nostrils to be inhaled, putting him to sleep.
Dried root powder and tinctures: used for antispasmodic and sedative purposes in European and Islamic herbal practice.
Topical extracts: M. autumnalis was regarded to produce irritant contact dermatitis upon topical exposure; erythema, swelling, and burning were reported upon the topical use of Mandragora root extract.
Ripe berries (dried): Historically, inhabitants of the Islamic Empire used M. autumnalis dried ripe berries to treat metabolic risk factors such as diabetes and obesity.

2. Traditional and Historical Use

Ancient Near East and Biblical Traditions

The oldest reliable textual source of a medicinal use of mandrake is considered to be the Old Testament (Genesis 30:14), mentioning its fruits as an aphrodisiac. It is native to the Mediterranean region and was familiar to the Romans, Greeks, and Middle Eastern cultures; it has a long history of medicinal use, and one of the oldest and most common uses was as a fertility aid — in Genesis, Jacob's wives, the sisters Leah and Rachel, compete to provide him with children with the help of mandrake. It was used as an analgesic and anesthetic by the Assyrians, and had both medicinal and spiritual importance in ancient Egypt.

Classical Greco-Roman Medicine

Several ancient authors cited mandrake as a powerful and well-known narcotic drug: from Homer to Dioscorides, from Plato to Aristotle, passing through Hippocrates, Demosthenes, Theophrastus, Celsus, and Apuleius; their detailed studies included the concrete appearance of the plant, the related recipes including mandrake as an essential ingredient, the right dosages, how to administer the obtained medication, and the possible collateral effects.

The most famous Roman medical writer, Dioscorides, who served as a doctor in Nero's army in the 1st century AD, wrote a massive pharmacological handbook called De Materia Medica, in which he described how to prepare these drugs for surgical use. Dioscorides, a Greek surgeon in the Roman army of Emperor Nero, recommends mandrake boiled in wine to "cause the insensibility of those who are to be cut or cauterized." The study reveals mandrake, classified by Dioscorides as 'Circe's root', was noted for inducing anaesthesia, with Hippocrates advising its use for painful procedures as early as 460 BCE.

In Naturalis historia, Pliny the Elder (23–79 AD) stated that mandrake-based drink was an excellent antidote for snake bites, but it was also useful before surgery (ante sectiones punctionesque).

Medieval European Medicine

Even in the Middle Ages, the success of this root continued: Isidore of Seville, Theodoric of Cervia, Gilbertus Anglicus, and William from Varignana extensively reported their research on sponges soaked with mandrake juice, which were used before surgical interventions as soporific tools. The use of mandrake as an anesthetic remedy entered medieval practice thanks to Isidore of Seville (560–636 AD), who, in an encyclopedic work of 20 books, described its characteristics and narcotic use.

In the medieval period, mandrake was also associated with witchcraft, believed to be an ingredient in "flying ointments" and magical potions. Elaborate rituals surrounded its harvest: its avenue to fame and popularity was paved by legends such as the deadly effect the plant would have on those who dig it up, wherefore it had been said that a dog should be used to complete the root-digger's job.

Islamic and Arab Medicine

Historically, inhabitants of the Islamic Empire used M. autumnalis dried ripe berries to treat metabolic risk factors such as diabetes and obesity, while its roots and leaves were used to treat a variety of illnesses, such as skin ulcers, infected wounds, pimples, warts, mouth inflammation, eye infections, pain, vomiting, male infertility, and insomnia. Arab physicians later developed the spongia somnifera, or "soporific sponge," which contained a mixture of plant juices, including mandrake, applied to the patient's nose to induce unconsciousness.

Scope of Traditional Indications

Mandragora officinarum (MO) is thought to be one of the magical herbs since the classical period; the plant belongs to the Solanaceae family and was popular among the Greeks, the Romans, the Arabs, and the Hebrews. Across these cultures, traditional uses included:

Sedation and surgical anesthesia (narcosis)
Analgesia (pain relief for surgery, rheumatism, and joint pain)
Aphrodisiac and fertility promotion: it was known throughout the Mediterranean and Levant for its use as an aphrodisiac and fertility enhancer.
Treatment of ulcers, inflammation, and eye disorders: Mandragora has a wide range of uses, including medicinal, hallucinogenic, and fertility-boosting applications, as well as the treatment of a variety of illnesses, including ulcers, inflammation, sleeplessness, and eye disorders.
Induction of hallucinations and management of mania and delirium: the plant can be used in hallucination, mania, and delirium, and can relieve certain joint pains and acts as a healing agent.

Decline in Medical Use

Mandrake has been in continuous medical use throughout written history and is still in use today in popular medicine; mandrake-derived drugs once played an important role in medicine and in magical practices; today, the role of mandrake in popular medicine is marginal; however, natural products present in mandrake such as atropine and scopolamine, as well as their semi-synthetic derivatives, continue to hold an important role in medicine. Anaesthetics with more reliable narcotic effects set the seal on using mandrake in surgery but opened the way for atropine being used as a prophylactic and antidote during surgical interventions.

3. Phytochemistry: Key Constituents and Active Compounds

Tropane Alkaloids (Primary Active Compounds)

All species of Mandragora contain highly biologically active alkaloids, tropane alkaloids in particular. Alkaloids present in the fresh plant or the dried root include atropine, hyoscyamine, scopolamine (hyoscine), scopine, cuscohygrine, apoatropine, 3-alpha-tigloyloxytropane, 3-alpha,6-beta-ditigloyloxytropane, and belladonnines.

Tropane alkaloids are the primary active compounds responsible for the pharmacological and toxicological properties of the plant; these alkaloids, concentrated mainly in the roots and leaves, include hyoscyamine and atropine (a racemic mixture of hyoscyamine); hyoscyamine predominates in many samples, exhibiting anticholinergic effects that influence the central nervous system, smooth muscle relaxation, and glandular secretion inhibition.

Hanuš et al. reviewed the phytochemistry of Mandragora species; more than 80 substances have been identified, with their paper giving the detailed chemical structure of 37 of them. Only two species, M. officinarum and M. turcomanica, have been extensively studied chemically.

The dried root of M. autumnalis contains tropane alkaloids, including atropine, scopine, scopolamine, cuscohygrine, hyoscyamine, apoatropine, norhyoscyamine, and belladonnines. Concentrations of these tropane alkaloids vary by plant part and environmental factors, with roots often showing higher levels.

The alkaloid mandragorine was initially thought to be the active substance of mandrake, but was later found to be a mixture of hyoscyamine and scopolamine.

Non-Alkaloid Phytochemicals

Mandragora has been shown to contain a variety of phytochemicals, including coumarins, withanolides, and alkaloids. A variety of phytochemicals have been isolated from Mandragora species, including lipid-like compounds (β-sitosterol), coumarins (umbelliferone and scopoletin), alkaloids (atropine and scopolamine), and withanolides (salpichrolide C).

Previous phytochemical studies of M. autumnalis resulted in the isolation of 11 alkaloids, including calystegine A3 and scopine, and a few coumarins such as scopoletin (4-methylesculetin), as well as the steroid sitosterol, in various parts of M. autumnalis roots, fruits, and leaves. Furthermore, several withanolides (polyoxygenated steroidal lactones/lactols) such as mandragorolide A were isolated from the M. autumnalis whole plant methanolic extract.

An earlier study showed that the ethanol extract of M. autumnalis leaves had significant levels of flavonoids and phenols along with other phytochemicals such as terpenoids, anthraquinones, coumarins, phlobatannins, and tannins; according to LC-MS analysis of the ethanol crude extract, quercetin 3,4′-diglucoside was detected in large proportions, followed by quinic acid, chlorogenic acid, and quercetin 4′-O-glucoside.

Among the principal compounds detected in LC-MS analysis were polyphenolic acids and their derivatives, including chlorogenic acid with high intensity, and caffeic acid; also, linolenic acid, a polyunsaturated fatty acid, coumarins with their derivatives including scopoletin, and 4-methylumbelliferyl acetate were present; furthermore, flavonoids and glycosides including rutin and hyperoside were identified.

Aromatic Volatile Compounds (Fruits)

The aromatic composition of Mandragora spp., first studied in 1992, resulted in the identification of 55 compounds through capillary GC/MS analysis of a methylene chloride extract of ripe fresh fruits of M. officinarum L.; the major compounds were ethyl butyrate (21.60%), hexanol (14.02%), and butyl acetate (9.08%).

4. Mechanisms of Action

Anticholinergic (Muscarinic Antagonism)

Mandragora officinarum contains tropane alkaloids, primarily hyoscyamine (which racemizes to atropine) and related compounds, that confer their primary pharmacological properties through competitive antagonism of muscarinic acetylcholine receptors. This competitive blockade at muscarinic receptors underlies the sedative, antispasmodic, antisecretory, and mydriatic effects historically observed with mandrake use. The alkaloids make the plant, in particular the root and leaves, poisonous, via anticholinergic, hallucinogenic, and hypnotic effects; anticholinergic properties can lead to asphyxiation.

Ancient authors, including Dioscorides and Hippocrates, documented mandrake's use for pain relief and sedation; mandrake's active components, such as hyoscyamine and scopolamine, induce unconsciousness and reduce pain sensitivity.

These anticholinergic properties can cause severe symptoms such as nausea, mydriasis, blurred vision, and supraventricular tachycardia; scopolamine can cause serious central nervous findings, presenting more often with an excited or agitated delirium, and less often with recent amnesia and suppression of the central nervous system.

Enzyme Inhibition

The pharmacological characteristics of M. autumnalis, such as increasing macrophage anti-inflammatory activity, free radical inhibition, bacterial and fungal growth inhibition, cytotoxic anticancer activities in vivo and in vitro against cancer cell lines, and enzyme-inhibitory properties, are attributed to its phytochemicals; furthermore, M. autumnalis also inhibits cholinesterase, tyrosinase, α-amylase, α-glucosidase, and free radicals.

Antioxidant Activity

These plant compounds are known to have biologically significant attributes, such as anticholinergic, antidepressant, antioxidant, and anti-inflammatory properties. As a result of its capacity to scavenge DPPH radicals, MAE demonstrated good antioxidant potential in vitro.

5. Scientific Evidence by Area of Use

Important framing note: There are no completed human clinical trials or randomized controlled trials (RCTs) examining Mandragora extracts as a therapeutic agent in modern medicine. Despite safety concerns, people sometimes use European mandrake for asthma, excessive crying in infants (colic), hay fever, and many other conditions, but there is no good scientific evidence to support these uses. All currently available pharmacological evidence beyond historical documentation is derived from in vitro (cell culture) experiments and animal models. The evidence for each area is characterized accordingly.

5.1 Sedation, Analgesia, and Anesthesia

Evidence level: Historical/ethnopharmacological; no modern clinical trials.

The use of mandrake as a sedative and surgical anesthetic is among the most thoroughly documented applications across history. Several ancient authors cited mandrake as a powerful and well-known narcotic drug; their detailed studies included the concrete appearance of the plant, the related recipes including mandrake as an essential ingredient, the right dosages, how to administer the obtained medication, and the possible collateral effects. The pharmacological plausibility of these uses is well-supported by the established mechanisms of its principal alkaloids: hyoscyamine and scopolamine act as central nervous system depressants and anticholinergics at muscarinic receptors, explaining the sedative and hypnotic effects reported historically.

No modern double-blind clinical trial has evaluated Mandragora extract for surgical sedation or analgesia. The development of safer, more reliable modern anesthetics rendered clinical investigation of whole-plant mandrake preparations unnecessary.

5.2 Anticancer Activity

Evidence level: In vitro and in vivo animal studies only; no human clinical evidence.

Ethanol crude extract and four solvent fractions were extracted from M. autumnalis leaves to evaluate their anticancer effect in both in vitro and in vivo models; the in vitro assessments were conducted using the MTT method in five cancer cell lines and one normal cell line; ethanol extract and n-hexane fraction showed antitumor activity against MCF-7 breast cancer cells with IC₅₀ values of 0.1 and 0.4 mg/ml, respectively, and low cytotoxicity against normal VERO cell line (IC₅₀ value > 4 mg/ml).

Expression levels of VEGF were tested in MCF-7 cells treated with M. autumnalis; the results indicated downregulation of VEGF expression in the treated cells compared to the control group. VEGF (vascular endothelial growth factor) is a key driver of tumor angiogenesis, and its downregulation is considered a potential anticancer mechanism.

A separate study on triple-negative breast cancer (TNBC) cells found that: M. autumnalis ethanolic leaf extract (MAE) diminished the viability of MDA-MB-231 cells in a concentration- and time-dependent manner; although MAE exhibited 55% radical scavenging activity at higher concentrations in the DPPH assay, the attenuation of its cytotoxic effects in MDA-MB-231 cells with N-acetylcysteine (NAC) co-treatment suggests a potential role of oxidative stress; additionally, MAE caused an increase in the tumor suppressor p53; moreover, this extract caused a significant decrease in the expression of Ki-67, MMP-9, and STAT-3.

Investigations into the pharmacological and phytochemical characteristics of M. autumnalis have revealed that this plant is a rich reservoir of new bioactive substances. More research on this plant is necessary to ensure its efficacy and safety; it is also necessary to understand the molecular mechanism of action behind the observed effects to clarify its therapeutic potential. All anticancer evidence to date is preclinical. No human trials have been conducted.

5.3 Antimicrobial Activity

Evidence level: In vitro studies only; no human clinical evidence.

Studies conducted in vitro have validated the biological characteristics of crude extracts from various parts of Mandragora, including their ability to modulate immunity, inhibit bacterial growth, prevent free radical-induced tissue damage, and inhibit several enzymes. Specifically, Mandragora autumnalis has been shown to have antibacterial, antioxidant, and antitumor properties in addition to exhibiting a narcotic effect. The plant has shown potential as a source of antimicrobial agents, particularly due to phenolic and flavonoid compounds with health benefits.

No clinical or human studies have evaluated Mandragora preparations as antimicrobial treatments. Findings remain limited to in vitro assay conditions.

5.4 Antidiabetic and Metabolic Effects

Evidence level: In vitro enzyme inhibition and historical ethnopharmacological use; no clinical trials.

M. autumnalis also inhibits cholinesterase, tyrosinase, α-amylase, α-glucosidase, and free radicals; additionally, metabolic risk factors, including the inhibition of diabetes-causing enzymes and obesity, have been treated using dried ripe berries. Inhibition of α-amylase and α-glucosidase is a recognized mechanistic target for blood glucose management, but the clinical relevance of these in vitro findings for Mandragora has not been established in human studies.

5.5 Anti-inflammatory Activity

Evidence level: In vitro and cellular studies; no human clinical evidence.

The pharmacological characteristics of M. autumnalis, such as increasing macrophage anti-inflammatory activity and free radical inhibition, are attributed to its phytochemicals. Phenols and flavonoids are recognized for their anticancer activity and anti-inflammatory and antioxidant functions. However, no clinical trials have evaluated this property in human subjects.

5.6 Antioxidant Activity

Evidence level: In vitro assay data; no clinical trials.

MAE exhibited 55% radical scavenging activity at higher concentrations in the DPPH assay. Antioxidant activity has been consistently demonstrated in various extract preparations in vitro, attributable to the plant's polyphenol, flavonoid, and coumarin content. Clinical significance for humans has not been studied.

5.7 Aphrodisiac and Fertility Effects

Evidence level: Traditional and ethnopharmacological; no modern clinical evidence.

The oldest reliable textual source of a medicinal use of mandrake is considered to be the Old Testament (Genesis 30:14), mentioning its fruits as an aphrodisiac. It was known throughout the Mediterranean and Levant for its use as an aphrodisiac and fertility enhancer. No controlled human studies have investigated these claims. The anticholinergic alkaloid profile of the plant does not provide an obvious pharmacological rationale for aphrodisiac or fertility-enhancing actions; a case of accidental poisoning involving a man who intentionally consumed mandrake berries for aphrodisiac purposes confirms that such use continues, with serious toxicological consequences. The cause of the poisoning was revealed by his girlfriend's disclosure that the patient had intentionally consumed some "aphrodisiac" berries to enhance his sexual performance.

6. Body Systems Associated with Mandrake

Central Nervous System: Sedation, narcosis, hallucination, delirium — mediated by anticholinergic alkaloids acting on muscarinic receptors in the brain.
Autonomic Nervous System / Parasympathetic: Inhibition of parasympathetic activity via muscarinic blockade; produces dry mouth, reduced secretions, and smooth muscle relaxation.
Cardiovascular System: Anticholinergic properties can cause severe symptoms such as supraventricular tachycardia. European mandrake may contain chemicals that can affect many body systems, including the bladder, eyes, and heart.
Ocular System: Mydriasis (pupil dilation) from muscarinic blockade; blurred vision is among the most consistently reported symptoms of both therapeutic and toxic exposure.
Gastrointestinal Tract: Antispasmodic via smooth muscle relaxation; historically used for stomach ulcers and colic. Ingesting mandrake root is likely to have adverse effects such as vomiting and diarrhea.
Urinary System: Difficulty of urination is a recognized anticholinergic effect; nine (60%) of poisoning cases had difficult micturition.
Immune System / Inflammation: In vitro evidence of macrophage anti-inflammatory activity and free radical inhibition.
Oncology (investigational): In vitro cytotoxic activity against cancer cell lines, including MCF-7 and MDA-MB-231 breast cancer cells.
Endocrine/Metabolic (investigational): In vitro inhibition of α-amylase and α-glucosidase relevant to diabetes-related enzyme targets.

7. Dosage Forms and Reported Dosages

There are no established safe therapeutic dosage ranges for Mandragora preparations in modern medicine. The alkaloid concentration varies between plant samples, and accidental poisoning is likely to occur. The following dosages have been recorded only in the context of scientific studies, not as clinical recommendations:

In vivo animal study (anticancer): The LD₅₀ of M. autumnalis ethanol extract was calculated by applying an acute toxicity assay; Balb/C mice were inoculated with EMT6/p breast cancer cells and then treated with 137 mg/kg/day intraperitoneal injection of ethanol extract for ten days.
In vitro (anticancer): Ethanol extract and n-hexane fraction showed antitumor activity against MCF-7 breast cancer cells with IC₅₀ values of 0.1 and 0.4 mg/ml, respectively.
Poisoning latency (clinical case series): In a case series of 15 patients with anticholinergic syndrome due to poisoning by Mandragora autumnalis, the latency period since ingestion was 1–4 hours (mean = 2.7 ± 0.9).
Treatment of poisoning: Treatment was aimed first at removing plant material from the gastrointestinal tract with a gastric lavage, and secondly towards the administration of cholinergic agents; both patients received 1 mg of physostigmine IV per day as treatment.

Historical preparations such as the mandrake wine used by Dioscorides do not have surviving quantified dosage records that can be verified pharmacologically.

8. Safety Considerations and Drug Interactions

General Toxicity

All parts of Mandragora species (leaves, seeds, berries, and roots) are poisonous, as they all contain tropane alkaloids, basically hyoscyamine and scopolamine. Mandragora autumnalis, a solanaceous plant, contains a variable concentration of solanum alkaloids, which cause gastrointestinal irritation, and tropane alkaloids, which have anticholinergic properties and produce typical and sometimes severe atropine-like symptoms. It may contain chemicals that can cause many side effects, including confusion, drowsiness, dry mouth, heart problems, vision problems, overheating, problems with urination, and hallucinations; large doses can be fatal.

Anticholinergic Syndrome: Clinical Toxicology

Anticholinergic syndrome (AS) due to accidental poisoning is exceptional; Mandragora contains a high concentration of atropine, hyoscyamine, and scopolamine; a published case series evaluated 15 patients with AS due to poisoning by Mandragora autumnalis, distributed in two family groups. All patients had blurred vision and dryness of mouth, nine (60%) had difficult micturition, nine dizziness, nine headache, eight (53%) vomit, two difficult swallowing, and two abdominal pain.

Misidentification is a primary cause of accidental poisoning. M. autumnalis is often mistaken for the edible Borago officinalis, likewise widespread in Sicilian countryside. A clinical case series of six patients from Sicily describes a parallel scenario: a 72-year-old female patient ate venomous M. autumnalis, picked near her home, mistaking it for the edible Borago officinalis.

Vital function support, decontamination, symptomatic treatment, and, in severe cases, antidote therapy with physostigmine are useful to control acute poisoning. Erythema, swelling, and burning were reported upon the topical use of Mandragora root extract.

Pregnancy and Lactation

European mandrake is likely unsafe when taken by mouth while pregnant or breast-feeding; it may contain chemicals that can affect the fetus and cause serious side effects; its use should be avoided.

Pediatric Use

European mandrake is likely unsafe when taken by mouth in children; children are especially sensitive to harmful chemicals it may contain.

Cardiovascular and Other Contraindications

Heart conditions including heart failure, coronary artery disease, and fast and irregular heartbeat constitute contraindications for European mandrake use. Additional conditions that have been identified as contraindications in clinical reference databases include glaucoma (do not take European mandrake if you have glaucoma), myasthenia gravis, kidney disease, high blood pressure, and over-active thyroid.

Drug Interactions

Because the primary alkaloids in Mandragora are competitive muscarinic receptor antagonists, pharmacodynamic interactions are expected with other agents that modulate cholinergic signaling or share anticholinergic properties. Documented or strongly anticipated interaction categories include:

Other anticholinergic medications: Additive anticholinergic burden — combining mandrake alkaloids with antihistamines, tricyclic antidepressants, antipsychotics, or bladder medications increases the risk of anticholinergic syndrome.
CNS depressants and sedatives: Potentiation of sedative and central nervous system depressant effects. Mandrake preparations have been historically taken in large doses with alcohol, opium, or laudanum.
Cholinesterase inhibitors (e.g., drugs used in Alzheimer's disease): Pharmacological antagonism; mandrake alkaloids would be expected to oppose the therapeutic effects of these agents.

More research on this plant is necessary to ensure its efficacy and safety; it is also necessary to understand the molecular mechanism of action behind the observed effects to clarify its therapeutic potential.

Regulatory and Contemporary Status

Mandrake is rarely used today due to toxicity, but it remains a subject of historical and pharmacological research. No major regulatory authority (EMA, FDA, WHO) has issued a positive therapeutic monograph for whole Mandragora preparations. Natural products present in mandrake such as atropine and scopolamine, as well as their semi-synthetic derivatives, continue to hold an important role in medicine — but as isolated, purified, and standardized pharmaceutical agents, not as crude plant preparations.

References

Health Conditions

Health conditions that Mandrake may help support.

No conditions available.

Body Systems

Body systems that Mandrake may help support.

No body systems available.